

Date: 30th June, 2020.

To,
BSE Limited,
Listing Compliance Department,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Ref : Script Id "BAJAJHCARE", Script Code "539872".

Sub: Disclosure under regulation 30 of the SEBI (Listing Obligation Disclosure Requirements) Regulation, 2015 (Outcome of Board Meeting).

We hereby inform you that the Board of Directors at their meeting held today i.e. 30th June, 2020 has inter-alia considered and approved the following:

- Audited Financial results for the quarter and year ended on 31st March, 2020 along with the Statutory Auditors' Report thereon.

The copy of approved financial results along with the Statutory Auditor's Report and Declaration required under regulation 33(3) (d) of SEBI (LODR) Regulation, 2015 are enclosed herewith.

- Appointment of Mr. Luke Fernandez (DIN 01110174) and Mrs. Kejal Shah (DIN 08608399) as Independent Directors on the Board of the Company.
- Appointment of Mr. Pakshal Jain (DIN 08776385) as Director on the Board of the Company.
- Re-appointment of Mr. Sajankumar Bajaj (DIN 00225950) as Chairman & Managing Director on the Board of the Company.
- Re-appointment of Mr. Anil Jain (DIN 00226137) as a Managing Director on the Board of the Company.
- Re-appointment of Mr. Dhananjay Hatle (DIN 00226390), Ms. Namrata Bajaj (DIN 05327071) & Mr. Rupesh Nikam (DIN 07007815) as Whole Time Directors on the Board of the Company.

Pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligation Disclosure Requirements) Regulation, 2015, the details required are enclosed as Annexure -I for appointment and re-appointment of Directors.

We wish to inform you that Board Meeting commenced today at 4.30 p.m. and concluded at 6.40 p.m.

You are requested to take the same on record.

Thanking you.

Yours faithfully,

**For and behalf of Board of Directors of
Bajaj Healthcare Limited**



**Aakash Keshari
Company Secretary**

Encl: As above

Annexure-I

Brief profiles:

Sr. No.	Details of Event(s) that Needs to be provided	Mr. Luke Fernandez	Mrs. Kejal Shah
1.	Reason for Change Viz. Appointment	Appointment as an Independent Director	Appointment as an Independent Director
2.	Date of Appointment & Term of Appointment	Appointment w.e.f. 30 th June, 2020 till the conclusion of ensuing General Meeting	Appointment w.e.f. 30 th June, 2020 till the conclusion of ensuing General Meeting
3.	Brief profile	Chartered Accountant by qualification and have served with the Unit Trust of India (UTI)/Unit Trust of India Asset Management Company Ltd. (UTI AMC) for 27 years and retired as Executive Vice President on 30th April 2017.	Company Secretary by qualification having experience in legal and secretarial matters.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not related to any Director of the Company nor disqualified to act as Director by any regulatory	Not related to any Director of the Company nor disqualified to act as Director by any regulatory

Sr. No.	Details of Event(s) that Needs to be provided	Mr. Pakshal Jain	Mr. Sajankumar Bajaj
1.	Reason for Change Viz. Appointment	Appointment as Director	Re-appointment as Chairman & Managing Director of the Company
2.	Date of Appointment & Term of Appointment	Appointment w.e.f. 30 th June, 2020 till the conclusion of ensuing General Meeting	For the period of 3 years subject to approval of shareholders at ensuing annual general meeting
3.	Brief profile	BME from Mumbai University, and having knowledge of marketing of API with manufacturing of formulation	Mr. Sajankumar R. Bajaj is a firm believer of honesty and transparency. Mr. Bajaj withholds the degree of Bachelors in Commerce. He has exponential experience in finance, marketing and material procurement, which led to appreciation of the company in very short time. As a CMD of such an organisation, he has set vision for our employees of consistency in improvement and excellence at each and every level.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not related to any Director of the Company except Mr. Anil Jain nor disqualified to act as Director by any regulatory.	Not related to any Director of the Company except Ms. Namrata Bajaj.

BAJAJ HEALTHCARE LIMITED



BAJAJ

Sr. No.	Details of Event(s) that Needs to be provided	Mr. Anil Jain	Mr. Dhananjay Hatle
1.	Reason for Change Viz. Appointment	Re-appointment as Managing Director of the Company	Re-appointment as Whole Time Director of the Company
2.	Date of Appointment & Term of Appointment	For the period of 3 years subject to approval of shareholders at ensuing annual general meeting	For the period of 3 years subject to approval of shareholders at ensuing annual general meeting
3.	Brief profile	He completed his diploma in pharmacy. Mr. Anil Jain with his balanced thought process, is the guiding light for company's expansion into international market. He is the staunch believer of knowledge is power and walks the path of knowledge and has taken the company to different heights.	Mr. Dhananjay Hatle is an Art Graduate from University of Mumbai. He is associated with our company for over 2 decades with an ideology of 'aiming high'. Mr. Hatle has earned experience in sales and marketing for Domestic market. His leading-edge marketing practices and energetic work rate proves to be an impetus to success of organization.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not related to any Director of the Company except Mr. Pakshal Jain.	Not related to any Director of the Company.

Sr. No.	Details of Event(s) that Needs to be provided	Ms. Namrata Bajaj	Mr. Rupesh Nikam
1.	Reason for Change Viz. Appointment	Re-appointment as Whole Time Director of the Company	Re-appointment as Whole Time Director of the Company
2.	Date of Appointment & Term of Appointment	For the period of 3 years subject to approval of shareholders at ensuing annual general meeting	For the period of 3 years subject to approval of shareholders at ensuing annual general meeting
3.	Brief profile	Ms. Namrata Bajaj holds the degree of "Bachelors in business administration" from "Indian Institution of Planning and management", Mumbai. She is working with the company from more than 10 years and has got a good experience in sales and marketing. She looks after the sales and marketing of Formulation division and has got the company to a good platform in formulation business with her dedication and hard work.	Mr. Rupesh Nikam is a Member of the Institute of Chartered Accountants of India (ICAI). He is working with the Company for over a decade and handles the entire portfolio of Accounts, Finance, Taxation, Costing, Auditing of Bajaj Healthcare Limited
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not related to any Director of the Company except Mr. Sajankumar Bajaj	Not related to any Director of the Company.

BAJAJ HEALTHCARE LIMITED

Registered Office: 602-606, Bhoomi Velocity Infotech Park, Plot No: B-39, B-39A, B-39A/1, Road No. 23, Wagle Ind. Estate, Thane (West), Thane - 400604
Tel. : + 91 22 66177400/ 401; Fax : +91 22 66177458; E-mail : bajajhealth@bajajhealth.com

CIN No. L99999MH1993PLC072892

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF BAJAJ HEALTHCARE LIMITED.

Report on the audit of the Standalone Financial Results Opinion

We have audited the accompanying standalone quarterly financial results of Bajaj Healthcare Limited (the company) for the quarter and year ended 31st March 2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit, other comprehensive income and other financial information for the quarter and year ended 31st March 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Standalone Financial Results

The Statements have been prepared based on Standalone Financial Statements. The Board of Directors of the Company are responsible for the preparation of these financial results that give a true and fair view of the net profit, other comprehensive income and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.



Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended for March 31, 2020 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2020 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under Listing regulations.

For Paresh Rakesh & Associates
Chartered Accountants
FRN: 119728W



Rakesh Chaturvedi
Partner

M. no: 102075
UDIN: 20102075AAAADW4351



Date: 30th June 2020
Place: Mumbai

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

STATEMENT OF ASSETS & LIABILITIES AS AT 31st MARCH 2020

(Rs in Lakhs)

	Particulars	As at 31.03.2020 (Audited)	As at 31.03.2019 (Audited)
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	a) Share Capital	1,379.92	689.96
	b) Reserves and Surplus	13,780.70	12,220.68
	Sub - Total - Shareholders' Funds	15,160.62	12,910.64
2	Non-current liabilities		
	a) Long - term borrowings	2,357.82	1,739.27
	b) Deferred Tax Liabilities (net)	220.62	158.91
	c) Long - term provisions	208.91	142.42
	Sub - Total - Non-current Liabilities	2,787.34	2,040.60
3	Current liabilities		
	a) Short - term borrowings	5,843.25	5,488.64
	b) Trade payables		
	(i) Total outstanding dues of micro enterprise & small enterprises	-	-
	(ii) Total outstanding dues of creditors other than micro enterprise & small enterprises	4,770.73	2,998.49
	c) Other current liabilities	3,095.66	2,561.91
	d) Short term provisions	916.93	684.47
	Sub - Total - Current Liabilities	14,626.57	11,733.51
	TOTAL - EQUITY AND LIABILITIES	32,574.53	26,684.76
B	ASSETS		
1	Non-Current Assets		
	a) Fixed Assets	14,017.08	12,967.50
	b) Non-Current investments	500.31	0.31
	Sub - Total - Non-Current Assets	14,517.38	12,967.81
2	Current Assets		
	a) Current investments	-	-
	b) Inventories	3,927.51	3,004.79
	c) Trade receivables	10,013.24	7,812.69
	d) Cash and cash equivalents	415.85	786.15
	e) Other current assets	3,700.56	2,113.32
	Sub - Total - Current Assets	18,057.15	13,716.95
	TOTAL ASSETS	32,574.53	26,684.76

Notes

1 The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in at their respective meeting held on 30th June 2020.

2 The Figures of the Previous year have been Re-grouped, Re-arranged, Re-Classified wherever considered necessary.

By Order of the Board
For Bajaj Healthcare Limited



Mr. Sajankumar R Bajaj
D.No.: 00225950
Managing Director

Date: 30th June 2020

Place: Thane

BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)

AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED AS ON 31ST MARCH, 2020

(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended		Year Ended	Year Ended
	31.03.2020	31.12.2019	31.03.2020	31.03.2019
	(Audited)	(UnAudited)	(Audited)	(Audited)
I. Revenue from operations	11,849.65	9,927.23	41,000.84	37,017.37
II. Other Income	286.09	12.30	317.91	97.17
III. Total Revenue (I+II)	12,135.74	9,939.53	41,318.74	37,114.55
IV. Expenses				
(a) Cost of materials consumed (Including Other Direct Expenses)	8,964.99	7,671.45	32,027.10	29,133.30
(b) Changes in Inventories of Finished Good	-367.73	-114.43	-508.76	-330.20
(c) Employee benefits expense	760.33	674.44	2,843.34	2,461.90
(d) Finance Costs	139.34	165.49	644.93	801.78
(d) Depreciation and amortisation expense	337.79	285.17	1,212.33	1,141.00
(c) Other expenses	900.18	334.03	1,854.66	1,489.79
Total Expenses	10,734.89	9,016.14	38,073.62	34,697.57
V. Profit before Exceptional and Extra Ordinary Items	1,400.85	923.39	3,245.13	2,416.98
VI. Exceptional items	-	-	-	-
VII. Profit before Extra Ordinary Items	1,400.85	923.39	3,245.13	2,416.98
VIII. Extra Ordinary items	-	-	-	-
IX. Profit Before Tax	1,400.85	923.39	3,245.13	2,416.98
X. Tax Expense				
(a) Current tax	370.00	290.00	910.00	675.00
(b) Deffered Tax	68.18	-4.93	61.71	38.92
(c) Earlier Years	2.62	0.31	23.44	72.02
Total Tax Expenses	440.80	285.38	995.15	785.95
XI. Profit (Loss) from Continuing Operations	960.05	638.01	2,249.98	1,631.03
XII. Profit (Loss) from Discontinuing Operations	-	-	-	-
XIII. Profit (Loss) for the period (XI + XII)	960.05	638.01	2,249.98	1,631.03
XIV. Paid-up Equity Share Capital (Face Value Rs. 10/-)	1,379.92	1,379.92	1,379.92	689.96
XV. Reserves excluding revaluation reserves as per Balance Sheet of Previous accounting Year	-	-	9,822.19	8198.25
XVI. EPS (Not Annualised) (Refer Note No. 6)				
(a) Basic	6.96	4.62	16.31	11.82
(b) Diluted	6.96	4.62	16.31	11.82

Note :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meeting held on 30th June 2020.
- The Financial Account of the Company are prepared under Indian GAAP as the Company was listed in SME segment of BSE Ltd as on 31st March 2019 and migrated to Main Board on 29th May 2019. Ind-AS will be applicable from 1st April 2020.
- Comparative Figures for Quarter ended 31st March 2019 are not provided, since the company was listed in SME segment until 31st March 2019 and was required to prepare & publish half yearly results instead of quaterly results upto 31st March 2019.
- The figures for the previous period have been regrouped whenever necessary.
- The Statement as per Accounting Standard AS - 17 on segment reporting is given as Anneuxre A.
- EPS has been calculated on 13799200 Number of Equity Shares of Rs.10 each, which includes Bonus Issue of 6899600 Fully paid up Equity Shares of Rs.10 each on April 11, 2019. Consequently the EPS for previous reporting periods are adjusted accordingly.
- An elobarate note on Impact of COVID-19 is given as an Annexure : B

By Order of the Board
For Bajaj Healthcare Limited



Mr. Sajankumar R Bajaj
D.No.: 00225950
Managing Director

Date: 30th June 2020
Place: Thane

BAJAJ HEALTHCARE LTD.
CASH FLOW STATEMENT FOR THE PERIOD 31st MARCH 2020
(CIN No. : L99999MH1993PLC072892)

(Rs. In Lakhs)

Sr No	Particulars	31st MARCH, 2020		31st MARCH, 2019	
		Amt in Rs.	Amt in Rs.	Amt in Rs.	Amt in Rs.
A	<u>CASH FLOW FROM OPERATING ACTIVITIES</u>				
	Net Profit Before Tax		3,245.13		2,416.98
	Adjustments for:				
	Depreciation	1,212.33		1,141.00	
	(Profit)/loss on sale of Assets	(2.71)		15.54	
	Interest & Finance Charges	644.93		801.78	
	Interest on FD	(30.88)		(24.92)	
	Provision for Employee Benefits & Leave Enchashment	91.69		72.97	
	Insurance Claim Receivable	-		-	
	Dividend Income	(0.04)	1,915.31	(0.04)	2,006.32
	Operating Profit before Working Capital Changes		5,160.44		4,423.30
	Adjustments for:				
	(Increase)/Decrease in Other current assets	(1,373.49)		113.72	
	(Increase)Decrease In Sundry Debtors	(2,200.55)		225.76	
	(Increase)/Decrease In Inventories	(922.72)		361.17	
	Increase /[(Decrease)] in non current and current liabilities	2,306.00		(1,304.65)	
			(2,190.77)		(604.00)
	Cash generated from operations		2,969.67		3,819.30
	Income Tax Paid		(912.19)		(1,302.44)
	Net Cash flow from Operating activities		2,057.49		2,516.87
B	<u>CASH FLOW FROM INVESTING ACTIVITIES</u>				
	Purchase of Fixed Assets	(1,842.15)		(1,500.59)	
	Increase/(Decrease) in Capital Wip	(426.79)		79.06	
	Sale Of Fixed Assets	9.74		0.83	
	Interest on FD	30.88		24.92	
	Payment to Gratuity Fund	(27.75)		(31.83)	
	Insurance Claim Received	-		125.00	
	Investment in Preference Shares	(500.00)		-	
	Dividend Income	0.04		0.04	
	Net Cash used in Investing activities		(2,756.02)		(1,302.56)
C	<u>CASH FLOW FROM FINANCING ACTIVITIES</u>				
	Proceeds From Long Term Borrowing	678.14		(360.38)	
	Increase of Investment in Preference Shares	-		-	
	Repayment Of Unsecured Long Term Borrowing	(59.59)		(47.87)	
	Increase /[(Decrease)] Of Short Term Borrowing From Bank	534.47		152.70	
	Increase /[(Decrease)] Of Borrowing From Director & Inter corporates	(179.86)		(116.21)	
	Interest paid	(644.93)		(801.78)	
	Dividend Paid	-		(69.00)	
	Dividend Distribution Tax Paid	-		(14.18)	
	Net Cash used in financing activities		328.23		(1,256.71)
	Net increase in Cash & Cash Equivalents (A+B+C)		(370.30)		(42.41)
	Cash and Cash equivalents as at 01.04.2019		786.15		828.56
	Cash and Cash equivalents as at 30.09.2019		415.85		786.15

For and on behalf of the Board

For BAJAJ HEALTHCARE LIMITED



Mr. Sajankumar R Bajaj
D.No.: 00225950
Managing Director

Place: Thane
Date: 30th June 2020

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER & PERIOD ENDED ON 31ST MARCH, 2020

Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended		Year Ended	Year Ended
		31.03.2020	31.12.2019	31.03.2020	31.03.2019
		(Audited)	(UnAudited)	(Audited)	(Audited)
A	Segment Revenue (Excluding Intersegment Revenue)				
	Bulk Drugs	11325.45	9326.81	38607.49	36155.31
	Formulations	595.16	600.42	2464.31	862.06
	Total	11,920.61	9,927.23	41,071.80	37,017.37
	Segment Revenue (Intersegment Revenue)				
	Bulk Drugs	617.67	503.27	2,108.98	676.41
	Formulations	23.78	20.54	86.18	85.10
	Total	641.44	523.81	2,195.15	761.51
	Gross Segment Revenue (Including Intersegment Revenue)				
	Bulk Drugs	11943.12	9830.08	40716.46	36831.72
	Formulations	618.94	620.96	2550.49	947.17
	Total	12,562.06	10,451.04	43,266.95	37,778.88
B	II. Segment Results				
	Profit / (Loss) Before Tax & Finance Cost				
	Bulk Drugs	2556.05	1402.86	5,957.64	4,956.61
	Formulations	-115.68	7.65	-212.92	-248.06
	Total	2,440.37	1,410.51	5,744.72	4,708.55
	Less : Interest	139.34	165.49	644.93	801.78
Other Unallocable Expenditure (Net)	900.18	321.63	1,854.66	1,489.79	
Total Profit Before Tax	1,400.85	923.39	3,245.13	2,416.98	
C	I. Segment Assets				
	Bulk Drugs	28992.27	26738.22	28,992.27	25,099.65
	Formulations	3081.96	2322.07	3,081.96	1,584.80
	Others	500.31	500.31	500.31	0.31
	Total	32,574.53	29,560.59	32,574.53	26,684.76
	II. Segment Liabilities				
	Bulk Drugs	15489.68	13988.31	15,489.68	12,466.14
	Formulations	584.70	532.96	584.70	331.64
	Others	1339.53	838.75	1,339.53	976.33
	Total	17,413.91	15,360.02	17,413.91	13,774.11
	Total Capital Employed	15,160.62	14,200.57	15,160.62	12,910.64
	Total (II+III)	32,574.53	29,560.59	32,574.53	26,684.76

By Order of the Board
For Bajaj Healthcare Limited



Mr. Sajankumar R Bajaj
D.No.: 00225950
Managing Director

Place : Thane
Date: 30th June 2020

Bajaj Healthcare Ltd

Annexure : B

Impact of Covid-19 on the Business:

On March 11, 2020, the World Health Organization (WHO) officially declared COVID-19, the disease caused by novel coronavirus, a pandemic. It continued to progress and evolve from the year end till the date of signing of the results of the Company. Due to its nature, it is challenging at this juncture, to predict the full extent and duration of its impact on financial performance and business. However, management is closely monitoring the evolution of this pandemic and has evaluated and re-assessed its impact on all major class of assets, liabilities, income and expenditures which are likely to have significant impact on the operations, profitability and continuity of the business.

Areas of re-assessment include:

- a) **Asset impairment:** Our assets consist of Movable and Immovable properties (including Land, Building, Plant and Machinery), investments, unsettled receivables for trade and advances for trade. Units are operational, the investments are of long term in nature and receivable are being settled on the basis of contractual terms without any substantial delay/delinquencies. Management doesn't foresee any impairment on these assets.
- b) **Inventory:** The Company deals in Bulk Drugs and Formulation (Pharmaceuticals) without any adverse impact. Nature of inventory does not pose any physical and market risk and based on present market conditions management do not foresee any loss on account of sale or its ultimate collection.
- c) **Debt repayment:** Projected cash flow reflects ability of the company to discharge its debts in form of Term Loan and working capital loan as per contractual terms through realization of current assets.
- d) **Revenue:** Company operates in two different segments viz Bulk Drugs and Formulation. Both the Segments does not have any impact of Covid-19.
- e) **Government policies on Social norms, travelling restrictions etc.:** Units of the Company producing essential commodities are operating at full capacity. To stop the spread of the disease caused by novel coronavirus forced the Head office of the Company located in Thane to operate on 'work from home model'. The Company has successfully adapted the new working culture and is confident that such kind of temporary restrictions will not have adverse effect on the prospects of the Company.

Based on above, Management is of the view that till date there is no significant impact of COVID-19 which requires adjustment to the carrying value of its assets and liabilities and provide for losses. Management currently has an appropriate response plan in place. Management will continue to monitor and assess the ongoing development and respond accordingly.



Date: 30/06/2020.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Subject: Declaration pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

I, Rupesh H. Nikam, Chief Financial Officer of Bajaj Healthcare Limited (CIN: L99999MH1993PLC072892) having its registered office at 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39A, B-39 A/1, Rd No.23, Wagle Ind. Estate Thane West Thane- 400604 hereby declare that the Statutory Auditors of the Company M/s Paresh Rakesh & Associates (Firm Registration No. 119728W) have issued an Audit Report with unmodified opinion on Audited Financial Results of the Company (Standalone) for the quarter and year ended March, 31, 2020.


This disclosure is given in compliance to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations) 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations 2016 vide Notification no. SEBI/LAD/NRO/GN/2016-17/001 dated May 25, 2016 and Circular No. CIR/CFD/CMD/56/2016 dated May, 27, 2016.

Kindly take this declaration on your records.

Thanking you,

Yours faithfully.

For Bajaj Healthcare Limited



Mr. Rupesh Nikam
Chief Financial Officer

BAJAJ HEALTHCARE LIMITED